Access to orphan drugs in western Europe: Can more systematic policymaking really help to avoid different decisions about the same drug?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 15, Issue 4, 2015, Pages 557-559

  Kanters, Tim A ^a   Hakkaart, Leona ^a   Rutten Van Mölken, Maureen P M H ^a   Redekop, W Ken ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Access; Multi criteria decision analysis; Orphan drugs; Pompe disease; Reimbursement

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; IDURONATE 2 SULFATASE; LARONIDASE; ORPHAN DRUG;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ENZYME REPLACEMENT; FABRY DISEASE; FINANCIAL MANAGEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; MEDICAL DECISION MAKING; NETHERLANDS; PRACTICE GUIDELINE; RARE DISEASE; REIMBURSEMENT; REVIEW; UNITED KINGDOM; WESTERN EUROPE; DECISION MAKING; DRUG MANUFACTURE; ECONOMICS; EUROPE; GLYCOGEN STORAGE DISEASE TYPE II; HEALTH CARE DELIVERY; HEALTH INSURANCE; MANAGEMENT; RARE DISEASES;

DECISION MAKING; EUROPE; GLYCOGEN STORAGE DISEASE TYPE II; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; ORPHAN DRUG PRODUCTION; POLICY MAKING; RARE DISEASES; REIMBURSEMENT MECHANISMS; SCOTLAND;

EID: 84945905314     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.2015.1045882     Document Type: Review

References (20)

1. Joppi R, Bertele' V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol 2013; 69(4):1009-24
2. Vegter S, Rozenbaum MH, Postema R, et al Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Clin Ther 2010; 32(9):1651-61
3. Güngör D, De Vries JM, Hop WC, et al. Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy. Orphanet J Rare Dis 2011; 6(1):34
4. Kanters TA, Hagemans ML, Van der Beek NA, et al. Burden of illness of Pompe disease in patients only receiving supportive care. J Inherit Metab Dis 2011; 34:1045-52
5. Kishnani PS, Corzo D, Leslie N.D., et al. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009; 66(3): 329-35
6. Van der Ploeg AT, Clemens PR, Corzo D, et al A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010; 362(15):1396-406
7. Güngör D, Kruijshaar ME, Plug I, et al. Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 2013; 8(1):49
8. Scottish Medicines Consortium. Alglucosidase alfa 50mg powder for concentrate for solution for infusion (Myozyme) No. (352/07). 2007
9. All Wales Medicines Strategy Group. Use of alglucosidase alfa (Myozyme) within NHS Wales. 2006
10. National Specialised Commissioning Advisory Group. Policy on the funding of enzyme replacement therapy and substrate reduction therapy. 2008
11. Transparency Committee. Myozyme 50mg, powder for concentrate for solution for infusion. 2013
12. Agenzia Italiano Del Farmaco. Reimbursement and pricing of the specialized medicine for human use «Myozyme» (recombinant human a-glucosidase acid) authorized by the centralized European procedure by European Commission (Determination/C n. 111/06). [in Italian]. Gazetta Ufficiale 2006; 273
13. Denis A, Simoens S, Fostier C., et al. Policy for rare diseases and orphan drugs. 2009; 112A
14. Kanters TA, Redekop WK, Hakkaart L. Factors predicting reimbursement decisions on orphan drugs in eight countries. Value Health 2012; 15(7):A308
15. Kishnani PS, Corzo D, Nicolino M., et al. Recombinant human acid a-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007; 68(2): 99-109
16. Winkel LP, Van den Hout JM, Johanna MP, et al. Enzyme replacement therapy in late-onset Pompe's disease: A three-year follow-up. Ann Neurol 2004; 55(4):495-502
17. Williams A. Intergenerational equity: an exploration of the'fair innings' argument. Health Econ 1997; 6(2):117-32
18. McKie J, Richardson J. The rule of rescue. Soc Sci Med 2003; 56(12):2407-19
19. Bobinac A, van Exel NJ, Rutten FF, et al. Inquiry into the Relationship between Equity Weights and the Value of the QALY. Value Health 2012; 15(8): 1119-26
20. Mirelman A, Mentzakis E, Kinter E., et al. Decision-making criteria among national policymakers in five countries: a discrete choice experiment eliciting relative preferences for equity and efficiency. Value Health 2012; 15(3):534-9